CSIMarket Company Name, Ticker, Industry, else..


Champions Oncology Inc   (NASDAQ: CSBR)
Other Ticker:  
 

Champions Oncology Inc

CSBR's Fundamental analysis



Looking into Champions Oncology Inc growth rates, revenue grew by 16.56 % in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 2384

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 13.31 %

Champions Oncology Inc realized net income compared to net loss a year ago in II. Quarter 2024

• More on CSBR's Growth


Champions Oncology Inc
realized a net loss in trailing twelve months.

Champions Oncology Inc realized cash reduction of $ -0.2 per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.56.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.67.


• More on CSBR's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 442,736
 Net Income/Employee (TTM) $ -4,942
 Receivable Turnover (TTM) 5.8
 Tangible Book Value (Per Share $) 0.02

Champions Oncology Inc
realized net loss in trailing twelve months.

Champions Oncology Inc realized cash outflow of $ -0.2per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.56.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.67.

Champions Oncology Inc Price to Book Ratio is at 201.3 lower than Industry Avg. of 406.6. and higher than S&P 500 Avg. of 0.01

• More on CSBR's Valuation

•  Market Capitalization (Millions $) 137
•  Shares Outstanding (Millions) 14
•  Employees 121
•  Revenues (TTM) (Millions $) 54
•  Net Income (TTM) (Millions $) -1
•  Cash Flow (TTM) (Millions $) -3
•  Capital Exp. (TTM) (Millions $) 0
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 442,736
•  Net Income/Employee(TTM) $ -4,942
•  Receivable Turnover Ratio (TTM) 5.8
•  Tangible Book Value (Per Share $) 0.02

•  Market Capitalization (Millions $) 137
•  Shares Outstanding (Millions) 14
•  Employees 121
•  Revenues (TTM) (Millions $) 54
•  Net Income (TTM) (Millions $) -1
•  Cash Flow (TTM) (Millions $) -3
•  Capital Exp. (TTM) (Millions $) 0


    CSBR's Profitability Comparisons
Champions Oncology Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in II. Quarter 2024 to 5.43 % from 9.45 % in I. Quarter.

Champions Oncology Inc net profit margin of 5.4 % is currently ranking no. 16 in Biotechnology & Pharmaceuticals industry, ranking no. 151 in Healthcare sector and number 1777 in S&P 500.


Profitability by Segment
Total 5.4 %



  Ratio
•   Capital Ratio (MRQ) 1.95
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 21.86
•  Asset Turnover Ratio (TTM) 2.09
•  Inventory Turnover Ratio (TTM) -



Champions Oncology Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in II. Quarter 2024 to 5.43 % from 9.45 % in I. Quarter.

Champions Oncology Inc net profit margin of 5.4 % is currently ranking no. 16 in Biotechnology & Pharmaceuticals industry, ranking no. 151 in Healthcare sector and number 1777 in S&P 500.

• More on CSBR's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com